Limited coverage drugs – sulindac

Last updated on October 12, 2022

Special Authority requests can now be submitted online. It's simple and quick!

Generic name	sulindac
Strength	150 mg, 200 mg
Form	tablet

Special Authority criteria	Approval period
For the treatment of patients who have a: Diagnosis of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, gout or lupus OR Treatment failure on optimal doses of, or intolerance to, the following: ibuprofen, naproxen, diclofenac AND either celecoxib or meloxicam.	Indefinite

Special Authority criteria

Approval period

For the treatment of patients who have a:

Diagnosis of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, gout or lupus

Treatment failure on optimal doses of, or intolerance to, the following: ibuprofen, naproxen, diclofenac AND either celecoxib or meloxicam.

Indefinite

Practitioner exemptions

Practitioners in the following specialties are not required to submit a Special Authority request for coverage:

paediatrics
paediatric cardiology
paediatric general surgery
physical medicine and rehabilitation
rheumatology

Special notes

Treatment failure on or intolerance to the specific medications listed in the above criteria is required. Treatment failure on or intolerance to the following NSAIDs is not sufficient: ketorolac, mefenamic acid, diclofenac potassium, naproxen sodium.

Special Authority requests

Log in to eForms
HLTH 5328 - General Special Authority Request (PDF, 656KB)

Did you find what you were looking for?

The B.C. Public Service acknowledges the territories of First Nations around B.C. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.

More topics

Limited coverage drugs – sulindac

Practitioner exemptions

Special notes

Special Authority requests